

Sae-Won Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8748728/publications.pdf>

Version: 2024-02-01

199
papers

6,552
citations

53794

45
h-index

82547

72
g-index

201
all docs

201
docs citations

201
times ranked

11082
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea. <i>Cancer Research and Treatment</i> , 2023, 55, 334-343.	3.0	2
2	Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer. <i>Molecular Oncology</i> , 2022, 16, 2396-2412.	4.6	17
3	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 115-124.	10.7	147
4	Longitudinal monitoring of circulating tumor DNA (ctDNA) during disease course of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-189.	1.6	1
5	Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	0
6	Prognostic Impact of Extramural Lymphatic, Vascular, and Perineural Invasion in Stage II Colon Cancer: A Comparison With Intramural Invasion. <i>Diseases of the Colon and Rectum</i> , 2022, Publish Ahead of Print, .	1.3	2
7	Role of Dedicated Subspecialized Radiologists in Multidisciplinary Team Discussions on Lower Gastrointestinal Tract Cancers. <i>Korean Journal of Radiology</i> , 2022, 23, .	3.4	1
8	Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment. <i>British Journal of Cancer</i> , 2022, 127, 898-907.	6.4	13
9	Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. <i>Journal of Clinical Oncology</i> , 2022, 40, 3868-3877.	1.6	6
10	Phenotype-based single cell sequencing identifies diverse genetic subclones in CD133 positive cancer stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 558, 209-215.	2.1	3
11	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	7.0	27
12	Circulating Tumor Marker Isolation with the Chemically Stable and Instantly Degradable (CSID) Hydrogel ImmunoSpheres. <i>Analytical Chemistry</i> , 2021, 93, 1100-1109.	6.5	7
13	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021, 39, 1335-1347.	2.6	1
14	Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX. <i>Scientific Reports</i> , 2021, 11, 14609.	3.3	10
15	A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
16	Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. <i>Scientific Reports</i> , 2021, 11, 16333.	3.3	14
17	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 1096-1103.	3.0	9
18	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 98-107.e1.	2.4	15

#	ARTICLE	IF	CITATIONS
19	Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor Immune Microenvironment in Colorectal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 870-881.	7.0	37
20	Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial. <i>Scientific Reports</i> , 2020, 10, 19467.	3.3	10
21	Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. <i>PLoS ONE</i> , 2020, 15, e0232754.	2.5	19
22	Viable and high-throughput isolation of heterogeneous circulating tumor cells using tapered-slit filters. <i>Sensors and Actuators B: Chemical</i> , 2020, 321, 128369.	7.8	7
23	Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. <i>Journal of Biological Chemistry</i> , 2020, 295, 1105-1119.	3.4	25
24	378...A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. , 2020, , .		2
25	Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. <i>International Journal of Cancer</i> , 2019, 144, 389-401.	5.1	48
26	Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Clinical Cancer Research</i> , 2019, 25, 6141-6147.	7.0	98
27	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage III breast cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 230-236.	6.4	14
28	Prognostic effects of abnormal DNA damage response protein expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 117-127.	2.5	8
29	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2019, 24, 1037-e636.	3.7	4
30	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. <i>BMC Cancer</i> , 2019, 19, 421.	2.6	2
31	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 453-460.	2.5	9
32	Results of re-irradiation for pelvic recurrence in anorectal cancer patients. <i>British Journal of Radiology</i> , 2019, 92, 20180794.	2.2	3
33	p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2019, 120, 797-805.	6.4	32
34	NFATC3-PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines. <i>Cancer Research and Treatment</i> , 2019, 51, 391-401.	3.0	13
35	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapelRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 711-711.	1.6	0
36	Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1642-1648.e2.	3.8	15

#	ARTICLE	IF	CITATIONS
37	<scp>FGFR</scp>2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers <i>in vitro</i>. <i>Molecular Oncology</i> , 2018, 12, 993-1003.	4.6	28
38	Epithelial and mesenchymal circulating tumor cell isolation and discrimination using dual-immunopatterned device with newly-developed anti-63B6 and anti-EpCAM. <i>Sensors and Actuators B: Chemical</i> , 2018, 260, 320-330.	7.8	18
39	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 252.	2.6	7
40	The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1186-1193.	3.0	17
41	Association Between <i>Fusobacterium nucleatum</i> , Pathway Mutation, and Patient Prognosis in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 3389-3395.	1.5	69
42	Novel graded prognostic assessment for colorectal cancer patients with brain metastases. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1112-1120.	2.2	9
43	A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 777-785.	2.3	21
44	Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. <i>Molecular Oncology</i> , 2018, 12, 1398-1409.	4.6	10
45	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174.	5.3	13
46	Prognostic implication of antitumor immunity measured by the neutrophilâ€“lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 254-262.	5.3	51
47	Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 158-162.	1.3	1
48	Polyester fabric sheet layers functionalized with graphene oxide for sensitive isolation of circulating tumor cells. <i>Biomaterials</i> , 2017, 125, 1-11.	11.4	25
49	Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. <i>Cancer</i> , 2017, 123, 3513-3523.	4.1	50
50	High-purity capture and release of circulating exosomes using an exosome-specific dual-patterned immunofiltration (ExoDIF) device. <i>Nanoscale</i> , 2017, 9, 13495-13505.	5.6	116
51	Enhancement of isolation sensitivity for the viable heterogeneous circulating tumor cells swelled by hypo-osmotic pressure. <i>RSC Advances</i> , 2017, 7, 49684-49693.	3.6	15
52	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	7.0	107
53	Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 757-764.	6.4	27
54	Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 147-153.	1.0	11

#	ARTICLE	IF	CITATIONS
55	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017, 8, 2329-2341.	1.8	50
56	Korean Cancer Patients's Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017, 49, 1033-1043.	3.0	19
57	Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. <i>Journal of Breast Cancer</i> , 2017, 20, 347.	1.9	13
58	A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 681-681.	1.6	4
59	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. <i>PLoS ONE</i> , 2017, 12, e0189848.	2.5	190
60	Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. <i>Oncotarget</i> , 2017, 8, 79441-79452.	1.8	26
61	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 454-463.	3.0	1
62	Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Cancer Research and Treatment</i> , 2017, 49, 1153-1163.	3.0	9
63	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 416-416.	1.6	1
64	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 460-460.	1.6	0
65	Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 454-454.	1.6	0
66	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016, 7, 58007-58021.	1.8	63
67	Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 346-349.	1.3	5
68	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
69	Dynamic cohesin-mediated chromatin architecture controls epithelial-mesenchymal plasticity in cancer. <i>EMBO Reports</i> , 2016, 17, 1343-1359.	4.5	21
70	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1515-1524.	4.1	10
71	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515.	2.6	11
72	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	6.4	19

#	ARTICLE	IF	CITATIONS
73	Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients. <i>Clinical Epigenetics</i> , 2016, 8, 36.	4.1	14
74	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016, 68, 750-755.	2.0	0
75	Diffusion-Related MRI Parameters for Assessing Early Treatment Response of Liver Metastases to Cytotoxic Therapy in Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2016, 207, W26-W32.	2.2	36
76	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 164-171.	6.4	43
77	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 233-241.	2.5	10
78	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 707-714.	2.5	8
79	Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability. <i>Nucleic Acids Research</i> , 2016, 44, 558-572.	14.5	18
80	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016, 19, 421-430.	5.3	11
81	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 597-606.	5.3	31
82	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3502-3502.	1.6	114
83	More Accurate Prediction of Metastatic Pancreatic Cancer Patients's Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016, 11, e0145692.	2.5	14
84	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016, 11, e0151406.	2.5	15
85	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	1.8	93
86	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 28-36.	3.0	20
87	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016, 48, 171-179.	3.0	56
88	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1045-1055.	3.0	10
89	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016, 48, 990-997.	3.0	15
90	TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4075-4075.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2016, 34, e23268-e23268.	1.6	0
92	Korean Cancer Patients's Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. Journal of Clinical Oncology, 2016, 34, 10067-10067.	1.6	0
93	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. Clinical Epigenetics, 2015, 7, 63.	4.1	17
94	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. BMC Cancer, 2015, 15, 690.	2.6	9
95	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer, 2015, 15, 721.	2.6	19
96	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Research, 2015, 17, 33.	5.0	138
97	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. PLoS ONE, 2015, 10, e0139749.	2.5	183
98	Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Journal of Breast Cancer, 2015, 18, 16.	1.9	38
99	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist, 2015, 20, 926-933.	3.7	15
100	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. Clinical Cancer Research, 2015, 21, 2520-2529.	7.0	59
101	Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. Materials, 2015, 8, 519-534.	2.9	6
102	Identification of Long-Range Epigenetic Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer. American Journal of Pathology, 2015, 185, 666-678.	3.8	6
103	A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 1175-1182.	2.3	1
104	The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 1833-1841.	1.7	6
105	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Research and Treatment, 2015, 152, 77-85.	2.5	17
106	KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX. Annals of Surgical Oncology, 2015, 22, 187-194.	1.5	52
107	Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0145004.	2.5	20
108	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2015, 47, 607-615.	3.0	93

#	ARTICLE	IF	CITATIONS
109	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3576-3576.	1.6	3
110	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. American Journal of Cancer Research, 2015, 5, 3376-88.	1.4	6
111	RNA editing in <i>RHOQ</i> promotes invasion potential in colorectal cancer. Journal of Experimental Medicine, 2014, 211, 613-621.	8.5	97
112	Ataxia-telangiectasia mutated protein expression with microsatellite instability in gastric cancer as prognostic marker. International Journal of Cancer, 2014, 134, 72-80.	5.1	42
113	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Investigational New Drugs, 2014, 32, 561-568.	2.6	2
114	Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemotherapy and Pharmacology, 2014, 73, 1021-1029.	2.3	14
115	Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 447-455.	2.3	4
116	The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. Journal of Pain and Symptom Management, 2014, 48, 13-25.	1.2	17
117	Comparison of concurrent chemoradiotherapy and chemotherapy alone for locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 351-351.	1.6	1
118	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Research, 2014, 34, 4275-80.	1.1	7
119	Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery. Anticancer Research, 2014, 34, 6685-90.	1.1	2
120	HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 109-115.	2.3	18
121	Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1435-1443.	2.3	15
122	Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 843-851.	2.3	37
123	Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. International Journal of Cancer, 2013, 132, 2209-2216.	5.1	49
124	Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. Cancer Chemotherapy and Pharmacology, 2013, 72, 1023-1029.	2.3	3
125	Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer, 2013, 16, 581-589.	5.3	28
126	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgical Oncology, 2013, 20, 2242-2249.	1.5	12

#	ARTICLE	IF	CITATIONS
127	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. <i>Cancer Letters</i> , 2013, 335, 145-152.	7.2	100
128	Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. <i>Experimental and Molecular Medicine</i> , 2013, 45, e64-e64.	7.7	51
129	Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 16-26.	4.1	57
130	RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 865-877.	4.1	116
131	Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02. <i>Journal of Clinical Oncology</i> , 2013, 31, 1732-1739.	1.6	78
132	Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors. <i>Journal of Breast Cancer</i> , 2013, 16, 66.	1.9	4
133	Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2013, 8, e64271.	2.5	71
134	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2565-2565.	1.6	1
135	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 492-492.	1.6	1
136	CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. <i>World Journal of Gastroenterology</i> , 2013, 19, 1438.	3.3	13
137	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013, 45, 325-333.	3.0	49
138	Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 182-182.	1.6	0
139	The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4044-4044.	1.6	3
140	Ki-67 level in hormone receptor positive breast cancer patients: A retrospective review of 9,061 Korean women.. <i>Journal of Clinical Oncology</i> , 2013, 31, 551-551.	1.6	5
141	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15066-e15066.	1.6	0
142	Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal) Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50	1.3	25
143	Adjuvant Chemoradiotherapy After Curative Resection for Extrahepatic Bile Duct Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 136-140.	1.3	35
144	Whole-Body Distribution and Radiation Dosimetry of ⁶⁸ Ga-NOTA-RGD, a Positron Emission Tomography Agent for Angiogenesis Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 65-71.	1.0	52

#	ARTICLE	IF	CITATIONS
145	Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 439-451.	4.1	62
146	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. <i>Anti-Cancer Drugs</i> , 2012, 23, 288-297.	1.4	21
147	Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. <i>Laboratory Investigation</i> , 2012, 92, 1033-1044.	3.7	34
148	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. <i>Investigational New Drugs</i> , 2012, 30, 2148-2160.	2.6	15
149	Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1133-1140.	2.5	13
150	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. <i>Cancer Letters</i> , 2012, 316, 77-84.	7.2	8
151	Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. <i>Cancer Letters</i> , 2012, 321, 128-136.	7.2	12
152	Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: Preliminary results of a prospective study. <i>European Journal of Radiology</i> , 2012, 81, 3542-3550.	2.6	21
153	Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e39943.	2.5	24
154	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data. <i>Journal of Breast Cancer</i> , 2012, 15, 427.	1.9	15
155	Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 1404-1412.	2.6	18
156	Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 391-395.	2.4	14
157	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 303-313.	2.9	64
158	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 395-403.	2.2	28
159	A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1003-1003.	1.6	2
160	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3076-3076.	1.6	6
161	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 269-269.	1.6	2
162	Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody. <i>PLoS ONE</i> , 2012, 7, e33322.	2.5	41

#	ARTICLE	IF	CITATIONS
163	Postoperative chemoradiotherapy in high risk locally advanced gastric cancer. <i>Radiation Oncology Journal</i> , 2012, 30, 213.	1.5	7
164	Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 623-623.	1.6	0
165	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3624-3624.	1.6	0
166	The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. <i>Anticancer Research</i> , 2012, 32, 1547-53.	1.1	28
167	Epigenetic-Based Therapies in Cancer. <i>Drugs</i> , 2011, 71, 2391-2403.	10.9	88
168	Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. <i>Cancer Letters</i> , 2011, 302, 155-165.	7.2	47
169	Antitumor activity of NVP-ANU922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. <i>Cancer Science</i> , 2011, 102, 1388-1395.	3.9	46
170	High serum TGF- β predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 107-114.	2.5	21
171	The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 637-641.	2.5	46
172	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1301-1308.	2.5	32
173	Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1323-1331.	2.3	34
174	Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 165-175.	2.3	7
175	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1017-1026.	2.3	6
176	Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1045-1055.	2.3	64
177	VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 143-147.	2.1	4
178	Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 94-100.	2.1	31
179	Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 593-599.	1.3	58
180	Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 125-129.	1.3	10

#	ARTICLE	IF	CITATIONS
181	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 320-325.	1.1	54
182	Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. <i>Cancer</i> , 2010, 116, 2890-2901.	4.1	53
183	Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. <i>Cancer Science</i> , 2010, 101, 793-799.	3.9	24
184	Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1537-1542.	2.8	29
185	The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer. <i>Journal of Breast Cancer</i> , 2010, 13, 90.	1.9	1
186	RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. <i>Cancer Letters</i> , 2010, 299, 22-28.	7.2	42
187	Angiogenesis Imaging Using ⁶⁸ Ga-RGD PET: Preliminary Report from Seoul National University Hospital. <i>Current Medical Imaging</i> , 2010, 6, 56-59.	0.8	1
188	Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma. <i>Anticancer Research</i> , 2010, 30, 5245-50.	1.1	5
189	Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2. <i>PLoS ONE</i> , 2009, 4, e5933.	2.5	91
190	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2526-2536.	4.1	65
191	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008, 61, 30-34.	2.0	89
192	Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 607-615.	4.1	50
193	Central Pontine Myelinolysis in a Patient with Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation: A Case Report. <i>Journal of Korean Medical Science</i> , 2008, 23, 324.	2.5	11
194	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 821-836.	3.1	12
195	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 313-319.	1.5	54
196	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 344-350.	1.3	29
197	Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. <i>Clinical Cancer Research</i> , 2006, 12, 2538-2544.	7.0	245
198	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®; ZD1839) in chemotherapy-resistant non-small cell lung cancer. <i>International Journal of Cancer</i> , 2005, 113, 109-115.	5.1	152

#	ARTICLE	IF	CITATIONS
199	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Nonâ€“Small-Cell Lung Cancer Patients Treated With Gefitinib. <i>Journal of Clinical Oncology</i> , 2005, 23, 2493-2501.	1.6	736